Satipharm, the makers of CBD Gelpell® capsules, has today announced it will sponsor a series of educational seminars, run by Medical Cannabis Research Australia (MCRA), to be held throughout the country in March. These seminars are an important source of clinical information for healthcare professionals and the talks will be by prescribers, pharmacists, patient advocates and other healthcare professionals.
Medicinal Cannabis was legalised in Australia in November 2016. The global legal cannabis market is expected to grow to over US$20 billion by 2020. There is good clinically-trialled evidence that cannabis-based medicines may be of benefit in chronic pain, multiple sclerosis, chemotherapy-induced nausea and vomiting as well as treatment-resistant epilepsy.
Jonathan Hartshorn, CEO Satipharm commented,
“We are proud to support an organisation that is dedicated to the education of healthcare professionals on the use of medicinal cannabis. We know from the families in Australia that use our CBD Gelpell® capsules, that cannabinoids have the power to dramatically transform the quality of life in many patients who have no other therapeutic options. We hope that the education provided by this event will see more people’s lives transformed using medicinal cannabis.”
This event continues Satipharm’s commitment to support research and education around medical cannabis. In July 2018, Satipharm completed a phase 2 clinical study to test Satipharm’s proprietary 50mg CBD Gelpell® capsules in paediatric patients with very severe, uncontrolled, treatment-resistant epilepsy (TRE).
In this pilot study, Satipharm CBD 50mg Gelpell® capsules were safe for use and demonstrated a potent seizure-reducing effect among paediatric TRE patients. This result was achieved with Satipharm CBD 50mg Gelpell® capsules that do not contain the psychoactive cannabinoid THC.
Accessing 50mg Gelpell® Capsules
Information for patients in Australia:
Satipharm CBD 50mg Gelpell® capsules are available in Australia through the Therapeutic Goods Administration (TGA) Special Access Scheme (Category B) or through the Authorised Prescriber Scheme. Patients wishing to access medicinal cannabis products should discuss access with their physician and make themselves familiar with the processes by reading the TGA advice at www.tga.gov.au
Information for patients in New Zealand:
Cannabidiol (CBD) is a prescription medicine under the Medicines Act 1981 in New Zealand. Ministry of Health approval is not required to prescribe, supply or administer CBD products for medical purposes.
Authorised prescribers and pharmacies are allowed to import CBD products, as are persons or companies holding a licence to sell medicines by wholesale. Importantly, individual patients may import CBD products provided they have a valid prescription. As with all prescription medicines, patients must have a prescription from an authorised prescriber to import or use CBD products.
If you are a patient and interested in using CBD for a medical purpose, please talk to your doctor as a first step. A maximum of three months’ supply is allowed on a prescription for CBD products.
Please contact us directly at email@example.com if you would like more information or to order Satipharm Gelpell®Capsules.
The MCRA’s mission is to help bring Medical Cannabis to those who need it by helping fund those researching the possibilities, educating those who can prescribe it and advocating to those who can make it available to everyone on behalf of patients everywhere. They are a Not-for-Profit Registered Australian Charity seeking to improve the quality of life of patients for whom conventional medicines have failed. Educate. Advocate. Research. https://mcra.org.au